CARMEL, Ind., Oct. 24, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

Shares of NeurAxis, Inc. NRXS have lost 0.8% since the company reported its earnings for the quarter ended June 30, 2025. This compares unfavorably with the S&P 500 Index’s 1.2% gain during the same ...

Shares of NeurAxis, Inc. NRXS have gained 41.2% since it reported earnings for the quarter ended Sept. 30, 2024. This strong performance contrasts with the S&P 500 index, which saw a decline of 0.9% ...

CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...

Neuraxis intends to raise $33.3 million in gross proceeds from an IPO of its common stock, although the final figure may vary. No existing shareholders have indicated an interest in purchasing shares ...

The US Food and Drug Administration (FDA) has cleared NeurAxis’ percutaneous electrical nerve field stimulation (PENFS) system for treating pain linked with a chronic type of gastrointestinal disorder ...

Shares of NeurAxis, Inc. NRXS have gained 13.3% since the company reported its earnings for the quarter ended March 31, 2025. This compares to the S&P 500 Index’s 4.3% growth over the same time frame.

NeurAxis, Inc. ((NRXS)) has held its Q3 earnings call. Read on for the main highlights of the call. NeurAxis, Inc. recently held its earnings call, revealing a mixed sentiment characterized by strong ...

Achieves significant expansion of NeurAxis’ total addressable market Clearance now includes patients aged “8 years and older” Expanded age indication will utilize the upcoming January 1 st, 2026, ...

. Seamless go-to-market strategy with existing reimbursement and provider infrastructure CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the“Company”) (NYSE American: ...